Research
Molecular
The review discusses the impact of metabolic drugs on inflammatory comorbidities of metabolic disorders.
Understanding the role of metabolic drugs in managing inflammatory comorbidities can enhance treatment strategies.
StrongSupportsmedium confidence
In this review, we discuss the impact of metabolic drugs on inflammatory comorbidities of metabolic disorders and beyond.
Why this rating
The abstract indicates a comprehensive review of existing literature.
Source
Repurposing metabolic drugs as anti-inflammatory agents
Andrew E. Hogan et al. · Trends in Endocrinology and Metabolism · 2025
DOI 10.1016/j.tem.2025.07.003
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →